Amir Emtiazjoo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Amir Emtiazjoo has a total of 47 co-authors. Here are the top co-authors by number of shared publications:
- Andrés Leon-Peña
Division of Cardiopulmonary Transplantation and Mechanical Circulatory Support, Michael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, TX 77030, USA
2 shared publications - Asishana Avo Osho
Massachusetts General Hospital, Harvard Medical School
2 shared publications - Cedric Vanluyten
Department of Thoracic Surgery, University Hospitals Leuven, Leuven, Belgium
2 shared publications - Dirk Van Raemdonck
Department of Thoracic Surgery, University Hospitals Leuven, Leuven, Belgium
2 shared publications - Fabio Ius
Department of Cardiothoracic, Transplant, and Vascular Surgery, Hannover Medical School, Hannover, Germany
2 shared publications - Kamrouz Ghadimi
Department of Anesthesiology, Duke University, Durham, North Carolina
2 shared publications
Latest Publications
- Open Access
- 16 June 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (12) , e047053
Survival With β‐Adrenergic Suppression After Lung Transplantation
Background: Survival following lung transplant (LT) surgery presents an ongoing challenge, and adverse LT outcomes are linked to cardiac arrhythmias. Current guidelines indicate that the role of β‐adrenergic suppression (BAS) after LT remains unclear. Methods: This retrospective observational study included adult patients who underwent LT at the University of Florida between 2016 and 2021. Their pre‐ and post‐LT antiarrhythmic medication use was correlated with long‐term survival after a 10‐day post‐LT blanking window. Results: The LT recipients (N=299) had a mean age of 60±11 years, 45% were women, and mean body mass index was 26±6 kg/m 2 . Available mean follow‐up was 4.5±1.9 years. The primary analysis included 299 patients, of whom 209 (70%) were prescribed BAS. Prescription of BAS after LT correlated with prolonged survival, even after adjusting for potential confounders ( P =0.008). A comparable survival benefit was observed in patients who continued BAS from pre‐LT to those who were newly initiated on BAS after LT, relative to patients not receiving BAS ( P =0.03 and P =0.03, respectively). No survival benefit was observed for other classes of antiarrhythmic drugs used after LT. Conclusions: This large, retrospective, single‐center study identified a correlation between BAS prescriptions and prolonged survival following LT. This association applied to both patients initiating BAS after transplant and those continuing preexisting BAS therapy. These findings underscore the promise of BAS in this population, and further prospective studies are warranted to confirm the beneficial role of BAS after LT.
- 16 June 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (12) , e047053
Open AccessSurvival With β‐Adrenergic Suppression After Lung Transplantation
Background: Survival following lung transplant (LT) surgery presents an ongoing challenge, and adverse LT outcomes are linked to cardiac arrhythmias. Current guidelines indicate that the role of β‐adrenergic suppression (BAS) after LT remains unclear. Methods: This retrospective observational study included adult patients who underwent LT at the University of Florida between 2016 and 2021. Their pre‐ and post‐LT antiarrhythmic medication use was correlated with long‐term survival after a 10‐day post‐LT blanking window. Results: The LT recipients (N=299) had a mean age of 60±11 years, 45% were women, and mean body mass index was 26±6 kg/m 2 . Available mean follow‐up was 4.5±1.9 years. The primary analysis included 299 patients, of whom 209 (70%) were prescribed BAS. Prescription of BAS after LT correlated with prolonged survival, even after adjusting for potential confounders ( P =0.008). A comparable survival benefit was observed in patients who continued BAS from pre‐LT to those who were newly initiated on BAS after LT, relative to patients not receiving BAS ( P =0.03 and P =0.03, respectively). No survival benefit was observed for other classes of antiarrhythmic drugs used after LT. Conclusions: This large, retrospective, single‐center study identified a correlation between BAS prescriptions and prolonged survival following LT. This association applied to both patients initiating BAS after transplant and those continuing preexisting BAS therapy. These findings underscore the promise of BAS in this population, and further prospective studies are warranted to confirm the beneficial role of BAS after LT.
- Open Access
- 15 December 2025
- Published by Elsevier in Transplantation Reports
- Vol. 11 (1)
Short telomere syndrome in lung transplantation: What do we know so far?
- 15 December 2025
- Published by Elsevier in Transplantation Reports
- Vol. 11 (1)
Open AccessShort telomere syndrome in lung transplantation: What do we know so far?
- Open Access
- 9 October 2025
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 45 (2) , 242-250
Outcomes of central versus peripheral arterial cannulation for intraoperative extracorporeal membrane oxygenation support in lung transplantation
- 9 October 2025
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 45 (2) , 242-250
Open AccessOutcomes of central versus peripheral arterial cannulation for intraoperative extracorporeal membrane oxygenation support in lung transplantation